Powered by: Motilal Oswal
2026-11-03 09:58:18 am | Source: Accord Fintech
Viyash Scientific moves up as its arm incorporates wholly owned subsidiary in Vietnam
Viyash Scientific moves up as its arm incorporates wholly owned subsidiary in Vietnam

Viyash Scientific is currently trading at Rs. 221.40, up by 1.00 points or 0.45% from its previous closing of Rs. 220.40 on the BSE.

The scrip opened at Rs. 223.05 and has touched a high and low of Rs. 223.05 and Rs. 221.30 respectively. So far 2208 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 297.90 on 06-Jul-2026 and a 52 week low of Rs. 178.40 on 23-Mar-2026.

Last one week high and low of the scrip stood at Rs. 232.70 and Rs. 212.65 respectively. The current market cap of the company is Rs. 9829.24 crore.

The promoters holding in the company stood at 49.24%, while Institutions and Non-Institutions held 10.90% and 39.86% respectively. 

Viyash Scientific’s wholly owned subsidiary -- Alivira Animal Health has incorporated a wholly owned subsidiary namely ‘Alivira Vietnam Company’ in Vietnam. Consequently, Alivira Vietnam Company has become a step-down wholly owned subsidiary of the company. The incorporated entity ‘Alivira Vietnam Company’ is expected to undertake the importation, registration, marketing, sale and distribution of animal health products, active pharmaceutical ingredients (APIs), and phytogenic solutions in Vietnam.

The entity is proposed to commercialize its products primarily through a distributor network, while also catering directly to select strategic key accounts. It is expected to provide commercial, technical and marketing support to customers and business partners to facilitate market development and business growth in Vietnam.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here